The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience

被引：0
|
作者：
Nasikas, D. [1 ]
Fostira, F. [2 ]
Tsoulos, N. [3 ]
Fokianou, A. [1 ]
Kontogianni, P. [1 ]
Ntasiou, P. [1 ]
Xepapadakis, G. [1 ]
机构：
[1] IASO Hosp, Breast Clin 2, Athens, Greece
[2] NCSR DEMOCRITOS, Mol Diagnost Lab, Athens, Greece
[3] Genekor Med SA, Athens, Greece
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P152
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [1] The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
    Crolley, Valerie E.
    Marashi, Husam
    Rawther, Shabbir
    Sirohi, Bhawna
    Parton, Marina
    Graham, Janine
    Vinayan, Anup
    Sutherland, Stephanie
    Rigg, Anne
    Wadhawan, Anshu
    Harper-Wynne, Catherine
    Spurrell, Emma
    Bond, Hannah
    Raja, Fharat
    King, Judy
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 809 - 817
  • [2] The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
    Valerie E. Crolley
    Husam Marashi
    Shabbir Rawther
    Bhawna Sirohi
    Marina Parton
    Janine Graham
    Anup Vinayan
    Stephanie Sutherland
    Anne Rigg
    Anshu Wadhawan
    Catherine Harper-Wynne
    Emma Spurrell
    Hannah Bond
    Fharat Raja
    Judy King
    Breast Cancer Research and Treatment, 2020, 180 : 809 - 817
  • [3] The Impact of Oncotype DX Breast Cancer Assay Results on Clinical Practice - a UK Experience
    Crolley, V.
    Rawther, S.
    Chaabouni, N.
    Rigg, A.
    Wadhawan, A.
    King, J.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E98 - E99
  • [4] The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience
    Crolley, V. E.
    Marashi, H.
    Rawther, S. K. R.
    Parton, M.
    Graham, J.
    Vinayan, A.
    Sutherland, S.
    Rigg, A.
    Wadhawan, A.
    Harper-Wynne, C.
    Spurrell, E.
    Bond, H.
    Raja, F.
    King, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience
    Crolley, Valerie E.
    Marashi, Husam
    Rawther, Shabbir Khan Rajan
    Sirohi, Bhawna
    Parton, Marina
    Graham, Janine
    Vinayan, Anup
    Sutherland, Stephanie
    Rigg, Anne
    Wadhawan, Anshu
    Harper-Wynne, Catherine
    Spurrell, Emma
    Bond, Hannah
    Raja, Fharat
    King, Judy
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 557 - 558
  • [6] Impact of Oncotype DX™ on decision making in breast cancer clinical practice
    Oratz, R
    Paul, D
    Cohn, A
    Sedlacek, S
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S100 - S100
  • [7] Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience
    Zhu, Xiaofu
    Dent, Susan
    Paquet, Lise
    Zhang, Tinghua
    Graham, Nadine
    Song, Xinni
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (15) : 2544 - 2549
  • [8] Use of Oncotype DX in Bilateral Breast Cancer
    Li, Pamela
    Cate, Sarah
    Malamud, Stephen
    Chadha, Manjeet
    Gillego, Alyssa
    Boolbol, Susan
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 74 - 75
  • [9] The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
    Carlson, Josh J.
    Roth, Joshua A.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (01) : 13 - 22
  • [10] The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
    Josh J. Carlson
    Joshua A. Roth
    Breast Cancer Research and Treatment, 2013, 141 : 13 - 22
12345